A2/A2B to B deceased donor kidney transplantation in the Kidney Allocation System era.
Am J Transplant
; 24(4): 606-618, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38142955
ABSTRACT
Kidney transplantation from blood type A2/A2B donors to type B recipients (A2âB) has increased dramatically under the current Kidney Allocation System (KAS). Among living donor transplant recipients, A2-incompatible transplants are associated with an increased risk of all-cause and death-censored graft failure. In light of this, we used data from the Scientific Registry of Transplant Recipients from December 2014 until June 2022 to evaluate the association between A2âB listing and time to deceased donor kidney transplantation (DDKT) and post-DDKT outcomes for A2âB recipients. Among 53 409 type B waitlist registrants, only 12.6% were listed as eligible to accept A2âB offers ("A2-eligible"). The rates of DDKT at 1-, 3-, and 5-years were 32.1%, 61.4%, and 72.1% among A2-eligible candidates and 14.1%, 29.9%, and 44.1% among A2-ineligible candidates, with the former experiencing a 133% higher rate of DDKT (Cox weighted hazard ratio (wHR) = 2.192.332.47; P < .001). The 7-year adjusted mortality was comparable between A2âB and B-ABOc (type B/O donors to B recipients) recipients (wHR 0.780.941.13, P = .5). Moreover, there was no difference between A2âB vs B-ABOc DDKT recipients with regards to death-censored graft failure (wHR 0.771.001.29, P > .9) or all-cause graft loss (wHR 0.820.961.12, P = .6). Following its broader adoption since the implementation of the kidney allocation system, A2âB DDKT appears to be a safe and effective transplant modality for eligible candidates. As such, A2âB listing for eligible type B candidates should be expanded.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transplante de Rim
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article